AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, DOSE-ESCALATION, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6874281 IN COMBINATION WITH ATEZOLIZUMAB ±BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA